Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs
- PMID: 21918551
- DOI: 10.1038/gt.2011.130
Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs
Abstract
Adeno-associated viral vector 9 (AAV9) has recently been shown to penetrate the blood-brain barrier via intravascular administration, making it a good candidate for diffuse gene delivery. However, the potential side effects of systemic delivery are unknown. Intrathecal viral vector administration may be more invasive than intravenous injections, but it requires far less vector and it can be performed on an outpatient basis, making it an ideal route of delivery for clinical translation. A total of 12 domestic farm pigs (<20 kg) underwent a single-level lumbar laminectomy with intrathecal catheter placement for AAV9 delivery. Animals were perfused and the tissue was harvested 30 days after treatment. Gene expression was assessed by anti-green fluorescent protein immunohistochemistry. Although a single lumbar injection resulted in gene expression limited to the lumbar segment of the spinal cord, three consecutive boluses via a temporary catheter resulted in diffuse transduction of motor neurons (MNs) throughout the cervical, thoracic and lumbar spinal cords. We now present the first successful robust transduction of MNs in the spinal cord of a large animal via intrathecal gene delivery using a self-complementary AAV9. These promising results can be translated to many MN diseases requiring diffuse gene delivery.
Similar articles
-
Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery.Hum Gene Ther. 2011 Sep;22(9):1129-35. doi: 10.1089/hum.2011.008. Epub 2011 Jul 25. Hum Gene Ther. 2011. PMID: 21443428
-
Motor neuron transduction after intracisternal delivery of AAV9 in a cynomolgus macaque.Hum Gene Ther Methods. 2015 Apr;26(2):43-4. doi: 10.1089/hgtb.2015.041. Hum Gene Ther Methods. 2015. PMID: 25885277
-
Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.Hum Gene Ther. 2014 Jul;25(7):619-30. doi: 10.1089/hum.2014.011. Epub 2014 Apr 28. Hum Gene Ther. 2014. PMID: 24617515
-
Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.Brain Res. 2020 Jul 15;1739:146832. doi: 10.1016/j.brainres.2020.146832. Epub 2020 Apr 11. Brain Res. 2020. PMID: 32289279 Free PMC article. Review.
-
The advent of AAV9 expands applications for brain and spinal cord gene delivery.Expert Opin Biol Ther. 2012 Jun;12(6):757-66. doi: 10.1517/14712598.2012.681463. Epub 2012 Apr 20. Expert Opin Biol Ther. 2012. PMID: 22519910 Free PMC article. Review.
Cited by
-
Intrathecal administration of IGF-I by AAVrh10 improves sensory and motor deficits in a mouse model of diabetic neuropathy.Mol Ther Methods Clin Dev. 2014 Jan 15;1:7. doi: 10.1038/mtm.2013.7. eCollection 2014. Mol Ther Methods Clin Dev. 2014. PMID: 26015946 Free PMC article.
-
Mosaic dysfunction of mitophagy in mitochondrial muscle disease.Cell Metab. 2022 Feb 1;34(2):197-208.e5. doi: 10.1016/j.cmet.2021.12.017. Epub 2022 Jan 13. Cell Metab. 2022. PMID: 35030325 Free PMC article.
-
Intraneural convection enhanced delivery of AAVrh20 for targeting primary sensory neurons.Mol Cell Neurosci. 2014 May;60:72-80. doi: 10.1016/j.mcn.2014.04.004. Epub 2014 Apr 24. Mol Cell Neurosci. 2014. PMID: 24769104 Free PMC article.
-
Viral vectors for therapy of neurologic diseases.Neuropharmacology. 2017 Jul 1;120:63-80. doi: 10.1016/j.neuropharm.2016.02.013. Epub 2016 Feb 21. Neuropharmacology. 2017. PMID: 26905292 Free PMC article. Review.
-
Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII.Mol Ther. 2016 Feb;24(2):206-216. doi: 10.1038/mt.2015.189. Epub 2015 Oct 8. Mol Ther. 2016. PMID: 26447927 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources